Á¦ 19ȸ ´ëÇÑÅõ¼®Çùȸ Ãß°è ½ÉÆ÷Áö¿ò : 2018-09-08±³À°ÀÏÀÚ : 2018-09-08
±³À°Àå¼Ò : ÄÚ¿¢½º ÄÁº¥¼Ç¼¾Å¸ 2Ãþ ASEM Ballroom 201È£
±³À°ÁÖÁ¦ :
Á¦ 19ȸ ´ëÇÑÅõ¼®Çùȸ Ãß°è ½ÉÆ÷Áö¿ò ÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Åõ¼®Àü¹®ÀÇ ¿¬±¸È¸
´ã´çÀÚ : ±ÇÇöÁ¤
¿¬¶ôó : 02-521-0485
À̸ÞÀÏ :
office@e-kda.org ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 60,000¿ø
ºñ°í »çÀüµî·Ï (ÀÇ»ç:5¸¸¿ø, °£È£»ç:3¸¸¿ø) ÇöÀåµî·Ï (ÀÇ»ç:6¸¸¿ø, °£È£»ç:4¸¸¿ø)
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09¿ù 09ÀÏ 09:10~09:35 Clinical impacts of middle molecule uremic toxins ÃÖÇý¹Î(¸íÁöº´¿ø)
±³À°½Ã°£ 09¿ù 09ÀÏ 09:35~10:00 Expanded hemodialysis is better? ±èµµÇü(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 09¿ù 09ÀÏ 10:00~10:25 High volume HDF is better? ±è°æ¹Î(À»ÁöÀÇ´ë)
±³À°½Ã°£ 09¿ù 09ÀÏ 10:45~11:10 Early diagnosis and ways to improve outcomes ¼Û»óÇå(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 09¿ù 09ÀÏ 11:10~11:35 SGLT2 inhibition is really promissing? ¹ÚÀçÀ±(µ¿±¹ÀÇ´ë)
±³À°½Ã°£ 09¿ù 09ÀÏ 11:35~12:00 Diabetic kidney disease management in ESRD patients ½ÅÁ¤È£(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 09¿ù 09ÀÏ 12:00~13:00 Åõ¼® µî ¸¸¼ºÁúȯ ȯÀÚ¿¡¼ Æó·Å±¸±Õ Áúȯ°ú ¿¹¹æÁ¢Á¾ÀÇ Á߿伺 (Á¾±Ù´ç) À̵¿°Ç(¼¿ïÀÇ´ë)
±³À°½Ã°£ 09¿ù 09ÀÏ 13:00~13:30 Hepatitis C: To treat or Not to treat? (Hepatologist) Á¶¿µÀ±(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 09¿ù 09ÀÏ 13:30~13:50 CKD-MBD (Etelcalcetide, Sucroferric oxyhydroxide etc) °í°Áö(°í·ÁÀÇ´ë)
±³À°½Ã°£ 09¿ù 09ÀÏ 13:50~14:10 Hyperkalemia (Patiromer, etc) ÀÌÀåÇÑ(ºÐ´çÀç»ýº´¿ø)
±³À°½Ã°£ 09¿ù 09ÀÏ 14:10~14:30 Anemia (Iron sucrose, etc) Á¤Á¾Ã¶(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 09¿ù 09ÀÏ 14:50~15:10 Case I: Hyperthyroidism in HD patients ±â¿¬°æ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 09¿ù 09ÀÏ 15:10~15:30 Case II: Osteoporosis in HD patients Á¶ÀºÁ¤(°í·ÁÀÇ´ë)
±³À°½Ã°£ 09¿ù 09ÀÏ 15:30~15:50 Biomarkers predicting survival of patients treated with CRRT ¿Àµ¿Áø(¸íÁöº´¿ø)
±³À°½Ã°£ 09¿ù 09ÀÏ 15:50~16:10 Metabolic complications of patients with CRRT ¹ÚÁ¾ÇÏ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 09¿ù 09ÀÏ 16:10~16:30 Anticoagulant during CRRT in patients with high bleeding risk ¾ÈÁ¤³²(¼¿ïÀÇ´ë)